Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on May 6, 2026. The filing addresses a critical corporate governance event regarding the Company's continued listing status on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance status rather than operational financial performance.
Material Changes and Events
- Nasdaq Non-Compliance Notification: On May 1, 2026, Nasdaq notified the Company of non-compliance with the minimum 500,000 Publicly Held Shares requirement (Listing Rule 5550(a)(4)) and the $1.00 minimum bid price requirement (Listing Rule 5550(a)(2)).
- Restoration of Share Count: On May 4, 2026, third-party investors exercised pre-funded warrants, allowing the Company to regain compliance with the Publicly Held Shares Requirement.
- Extension Granted: On May 6, 2026, the Nasdaq Hearings Panel granted a one-day extension for the Company to demonstrate compliance with the Bid Price Rule. The deadline to evidence a closing bid price of at least $1.00 per share for 10 consecutive business days was extended from May 15, 2026, to May 18, 2026.
Outlook, Risks, and Management Commentary
Management states it is diligently working to satisfy the Panel's decision terms. However, the filing explicitly warns that there can be no assurance the Company will meet the requirements. Failure to comply by the new deadline will result in delisting from Nasdaq. The filing includes standard forward-looking statement disclaimers regarding the uncertainty of achieving these compliance targets.
Investor Verification Checklist
- Verify the Company's daily closing bid price to ensure it meets the $1.00 threshold for the required 10 consecutive business days ending May 18, 2026.
- Confirm the current number of publicly held shares remains above the 500,000 minimum following the warrant exercises.
- Monitor for any subsequent 8-K filings indicating a failure to meet the May 18, 2026 deadline, which would trigger delisting proceedings.
- Review the Company's most recent Form 10-K for detailed risk factors related to capital structure and liquidity.